|EGFR antagonists in cancer treatment|
F Ciardiello, G Tortora
New England Journal of Medicine 358 (11), 1160-1174, 2008
|Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes|
AV Biankin, N Waddell, KS Kassahn, MC Gingras, LB Muthuswamy, ...
Nature 491 (7424), 399, 2012
|A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor|
F Ciardiello, G Tortora
Clinical Cancer Research 7 (10), 2958-2970, 2001
|Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor|
F Ciardiello, R Caputo, R Bianco, V Damiano, G Pomatico, S De Placido, ...
Clinical Cancer Research 6 (5), 2053-2063, 2000
|Whole genomes redefine the mutational landscape of pancreatic cancer|
N Waddell, M Pajic, AM Patch, DK Chang, KS Kassahn, P Bailey, ...
Nature 518 (7540), 495, 2015
|Genomic analyses identify molecular subtypes of pancreatic cancer|
P Bailey, DK Chang, K Nones, AL Johns, AM Patch, MC Gingras, ...
Nature 531 (7592), 47, 2016
|Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor|
F Ciardiello, R Caputo, R Bianco, V Damiano, G Fontanini, S Cuccato, ...
Clinical cancer research 7 (5), 1459-1465, 2001
|ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases|
F Carlomagno, D Vitagliano, T Guida, F Ciardiello, G Tortora, G Vecchio, ...
Cancer research 62 (24), 7284-7290, 2002
|Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer|
G Di Lorenzo, G Tortora, FP D’Armiento, G De Rosa, S Staibano, ...
Clinical Cancer Research 8 (11), 3438-3444, 2002
|Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense …|
F Ciardiello, R Bianco, V Damiano, G Fontanini, R Caputo, G Pomatico, ...
Clinical Cancer Research 6 (9), 3739-3747, 2000
|Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor …|
F Ciardiello, R Caputo, V Damiano, R Caputo, T Troiani, D Vitagliano, ...
Clinical Cancer Research 9 (4), 1546-1556, 2003
|Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225|
F Ciardiello, R Bianco, V Damiano, S De Lorenzo, S Pepe, S De Placido, ...
Clinical Cancer Research 5 (4), 909-916, 1999
|Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth …|
F Ciardiello, R Bianco, R Caputo, R Caputo, V Damiano, T Troiani, ...
Clinical Cancer Research 10 (2), 784-793, 2004
|Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas|
Y Jiao, TM Pawlik, RA Anders, FM Selaru, MM Streppel, DJ Lucas, ...
Nature genetics 45 (12), 1470, 2013
|A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer|
M De Laurentiis, G Arpino, E Massarelli, A Ruggiero, C Carlomagno, ...
Clinical cancer research 11 (13), 4741-4748, 2005
|Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer|
J Tabernero, E Van Cutsem, E Díaz-Rubio, A Cervantes, Y Humblet, ...
Journal of clinical oncology 25 (33), 5225-5232, 2007
|Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin …|
G Fontanini, M De Laurentiis, S Vignati, S Chinè, M Lucchi, V Silvestri, ...
Clinical Cancer Research 4 (1), 241-249, 1998
|nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial|
D Goldstein, RH El-Maraghi, P Hammel, V Heinemann, V Kunzmann, ...
JNCI: Journal of the National Cancer Institute 107 (2), 2015
|Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in …|
L Carbognin, S Pilotto, M Milella, V Vaccaro, M Brunelli, A Calio, ...
PloS one 10 (6), e0130142, 2015
|Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa)|
C Bianco, G Tortora, R Bianco, R Caputo, BM Veneziani, R Caputo, ...
Clinical Cancer Research 8 (10), 3250-3258, 2002